1st May 2014, London: Pro Bono Bio (PBB), the world leader in nano-physical medical devices, is proud to announce that it has been appointed as an official supplier to top English premiership rugby club, Saracens, for their breakthrough joint-care product, FLEXISEQ®.

This announcement is the culmination of nearly 6 months of collaboration between PBB and the Saracens medical staff who have been trialling FLEXISEQ among players of their elite squad, since the product hit the UK market in early December 2013.

28th January 2014, London: Pro Bono Bio®, the global leader in nano-physical healthcare products, announces the UK national launch of FLEXISEQ™, the innovative drug-free, safe treatment for joint pain associated with osteoarthritis1 (OA) following the successful conclusion of the pioneering 2 month Charity partnership phase for the benefit of Arthritis Research UK. The contribution in products that are sold through the Arthritis Research UK website and through LloydsPharmacy has raised over £400,000 for the medical research charity. Sufferers have enthusiastically welcomed the new, effective and safe product that they can self-medicate and it is now going on sale through all leading pharmacies in the
UK.  FLEXISEQ comes with significant advantages as the product has no contra-indications, contains no drugs so cannot cause drug-to-drug interactions and so is safer than the existing drug treatments.

3rd December 2013, London: Pro Bono Bio®, the global leader in nano-physical healthcare products, announces the UK Charity launch of FLEXISEQ™, the innovative drug-free, safe treatment for joint pain associated with osteoarthritis1 (OA). FLEXISEQ's proven efficacy comes with significant advantages as the product has no contra-indications, contains no drugs so cannot cause drug-to-drug interactions, and with over 6 million doses administered since launch there have been no reported systemic side effects.

FLEXISEQ is already successfully sold in the early pilot markets of Austria, Germany, Ireland, Malaysia and Singapore. Earlier this year, FLEXISEQ won the Innovation Award 2013 from the Federal Association of German Pharmacists. In June, FLEXISEQ launched in Ireland and became the fastest growing over-the-counter product that pharmacies there had seen in recent times.

October 2013 – FLEXISEQ™, the award winning new drug-free treatment for Osteoarthritis is now available in Singapore.  Clinically proven* in Europe to be as effective at pain relief as the prescription drug celecoxib, but with an excellent safety profile, Flexiseq has been hailed in Europe as a Wondergel*. Flexiseq has already won The Innovation Award 2013 from the Federal Association of German Pharmacists for its break through Nano Technology.

Berlin 25.1013 "Get people moving – experience success". This slogan of the German Congress of Orthopaedics and Trauma Surgery also held true for the symposium organised by Pro Bono Bio, which reported on a new, innovative and award-winning therapy option for osteoarthritis patients. Studies were presented proving the efficacy of the topical gel for pain and joint stiffness associated with osteoarthritis as well as personal experiences of the presenters with FLEXISEQ™ based on patient cases. FLEXISEQ contains no pharmacologically active substances, but works through the use of Sequessome™ vesicles, tiny phospholipid droplets that penetrate the skin into the joint and lubricate the damaged cartilage. Worldwide marketing of the gel, developed and produced in Germany, is pending after initial successes in Europe and Asia, as company head John Mayo reported.

555 patient clinical trial provides further evidence that FLEXISEQ is effective in reducing pain for osteoarthritis patients with a particularly strong safety profile.

London, England 6 September 2013 –Key clinical trial data supporting Pro Bono Bio’s (“PBB”) drug-free osteoarthritis treatment FLEXISEQ, have been published in The Journal of Rheumatology. This is the latest high profile publication after winning the German Pharmacy Industry award for innovation in January 2013.

The publication reports that FLEXISEQ (TDT 064) was very effective in managing the pain associated with osteoarthritis (OA) and was again found to have a much stronger safety profile than other treatments.

Berlin, London, Dublin, Kuala Lumpur, Singapore, Valletta 20 June 2013

The renowned medical journal The Lancet has recently published a study by Oxford University, which confirms the potential dangers in a class of drugs commonly prescribed in patients with chronic diseases such as osteoarthritis. The study analysed the results of 754 clinical trials of Non Steroidal Anti Inflammatory (NSAID) Drugs, including diclofenac, ibuprofen, naproxen and the COX-II inhibitors: celecoxib, rofecoxib, etoricoxib and lumiracoxib. It confirmed that these drugs significantly increased risks of cardiovascular side effects, including death, and gastrointestinal problems including internal bleeding.

This is yet further confirmation of the potentially fatal risks of this commonly prescribed class of painkillers: In 2009 a Danish national cohort study involving millions of people showed that taking ibuprofen, diclofenac, naproxen, rofecoxib and celecoxib significantly raised the risk of death and heart attack, even after a short treatment period.

Dublin, Ireland 4 June 2013 – Pro Bono Bio® is pleased to introduce its new topical treatment for osteoarthritis, FLEXISEQ, to Ireland. Ireland has over 450,000 sufferers of this debilitating disease according to Arthritis Ireland and FLEXISEQ provides a versatile and novel treatment option for patients.

John Church, CEO of Arthritis Ireland said “We welcome any new innovative approach to making life easier for the 450,000 people living with osteoarthritis in Ireland. We look forward to hearing patient feedback on this drug-free product; and working with physicians to see where FLEXISEQ best fits in the treatment options of this chronic and painful disease”.

Professor Geraldine McCarthy from Mater Misericordiae University Hospital, in Dublin said “I have been aware of FLEXISEQ since its launch in Germany last year and welcome its arrival in Ireland, as we have a real need for new treatments for the symptoms of osteoarthritis. I look forward to hearing feedback from our patients.”

1300 patient clinical trial provides evidence that Pro Bono Bio’s innovative osteoarthritis treatment, FLEXISEQ, is as effective as an oral, prescription drug while having a distinctly favourable safety profile.

London, England 10 April 2013 –Key phase III trial data supporting Pro Bono Bio’s (“PBB”) drug-free osteoarthritis treatment FLEXISEQ, have been published today in Rheumatology, the official journal of the British Society for Rheumatology. The event is the latest high profile publication and achievement for the product after winning a German pharmacy award for innovation in January 2013.

The publication reports that FLEXISEQ (TDT 064)1, then a control arm in the reported trial, was equivalent to the oral NSAID celecoxib (the active comparator arm) and was better tolerated by patients. The findings offer hope to osteoarthritis patients, particularly those who are at risk from the common gastrointestinal and cardiovascular side effects associated with NSAIDs, such as celecoxib and diclofenac.

What is exciting is the extensive variety of joints patients have successfully used FLEXISEQ to treat.

Munich, Germany (PRWEB UK) 29 March 2013

Pro Bono Bio welcomes the results from an independent patient survey of its product, Flexiseq conducted by the German product-testing community, Feierabend.de. The survey was performed among the community’s osteoarthritis members capturing their “real-life” experiences of the product and producing results that complement Flexiseq's impressive clinical data.

Innovative New Treatment for the Symptoms of Osteoarthritis

Frankfurt/London 24th January 2013 – The Federal Association of German Pharmacists (BVDA) today presented its “Innovation Award 2013” to FLEXISEQ®, an innovative new treatment for pain and stiffness associated with osteoarthritis (OA).

Michael Earl receiving BVDA Award for FLEXISEQ

FLEXISEQ™ for Hajj Pilgrims

Wednesday, 13 June 2012 08:00

Pro Bono Bio™ Humanitarian Donation Dakar/London 11th June 2012

FLEXISEQ for Hajj PilgrimsPro Bono Bio is pleased to announce that its Humanitarian Division has made its first charitable donation of products following its commitment to help healthcare in Africa. The donation was made by Pro Bono Bio’s envoy Andrei Garbuz (pictured) to thehead of commission for pilgrimage to holy places of Islam, Mr El Hadji Mansour DIOP in Dakar. The Commissioner General commented "It is with great pleasure and genuine interest that I received the consignment of FLEXISEQ products, kindly made available to the Senegalese pilgrims for the 2012 Hajj. Experience gained from the previous Hajjes shows the point to which osteoarthritis affects the majority of our elderly pilgrims and is the subject of regular consultations with our medical team. This shows the great interest which our pilgrims, and we ourselves, have in such a gesture. Allow me, on behalf of all Senegalese pilgrims and the government of Senegal, to send you our sincere thanks."

New Osteoarthritis treatment for Malaysia

Kuala Lumpur/London 15th June 2012 - Pro Bono Bio™ is pleased to announce that its innovative product FLEXISEQ, a new nanotechnology based treatment for osteoarthritis, has received approval for sale in Malaysia. This follows the successful launch of FLEXISEQ in Europe earlier this year.

Pro Bono Bio is also pleased to announce that they have signed an agreement to distribute FLEXISEQ in Malaysia and the product will be available via local distribution company, Farmasia Sdn. Bhd. from early July 2012. Its first introduction to the local market is at the 42nd Annual Scientific Meeting of the Malaysian Orthopaedic Association in Kuantan, Malayisa held between the 14th and 17th of June 2012.




Visit FLEXISEQ Sports
Add us on facebook
Follow us on twitter
Check our Weibo site
Check our youtube channel